MedTrace Logo

Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis

NCT06319794 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-07-18

No results posted yet for this study

Summary

The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands

Conditions

  • Actinic Keratosis

Interventions

DRUG

Bimiralisib

Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks

DRUG

Bimiralisib

Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks

Sponsors & Collaborators

  • TORQUR

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-02
Primary Completion
2025-06-24
Completion
2025-06-24

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06319794 on ClinicalTrials.gov